ACR-368 is Acrivon Therapeutics' (NASDAQ: ACRV) lead asset — a dual CHK1/2 inhibitor in a registrational-intent Phase 2b study for serous endometrial cancer, with maturing data showing a 52% confirmed overall response rate. FDA granted Fast Track for the drug and Breakthrough Device designation for its companion OncoSignature assay in March 2026. The key near-term event is the Phase 2b prespecified interim analysis plus all-comer arm data, on track for 2H 2026. The stock closed around $2.20 (52-week range $1.27–$3.56) against a $11.50 mean analyst price target with 13 of 14 ratings at Buy/Strong Buy, and cash runway into Q2 2027.
IPH4502 is Innate Pharma's (NASDAQ: IPHA; Euronext Paris: IPH) Nectin-4-targeting antibody-drug conjugate (ADC) — a targeted cancer therapy in Phase 1 dose escalation. Innate reported (6-K, July 21, 2026) that enrollment in the Phase 1 study is complete (76 patients) with a favorable safety profile and objective responses in heavily pre-treated patients, and preliminary data are expected by year-end 2026; the company lists IPH4502 results as one of only three key 2026 pipeline catalysts. It is an early-stage, code-only program with no generic name or independent external coverage found this session, competing in a space already occupied by FDA-approved Padcev plus several next-gen Nectin-4 assets — and the parent company carries a cash-runway/going-concern overhang, partially mitigated by an August 2026 Sobi partnership on its lead asset lacutamab (not IPH4502).
2 drug reports
-
Tasigna (nilotinib) is Novartis' second-generation BCR-ABL tyrosine kinase inhibitor for Philadelphia-chromosome-positive chronic myeloid leukemia, approved by the FDA on October 29, 2007 and now indicated for adults and children ≥1 year with newly diagnosed chronic-phase Ph+ CML as well as resistant/intolerant disease. It is a mature, fully commercialized drug that lost US exclusivity in 2025 — Apotex launched the first generic nilotinib in the US on May 27, 2025 — and 2024 US sales were already ~$848M and eroding, with Novartis' own Q4 2025 release citing 'significant US generic entries' as a drag. There is no pending regulatory decision or pivotal readout for Tasigna, so it is a declining revenue line inside a diversified mega-cap rather than a binary story.
Explore drug → -
Entresto (sacubitril/valsartan) is Novartis's blockbuster heart-failure drug, approved by the FDA in July 2015 and expanded to a pediatric sprinkle form in April 2024 — but its US patent protection has now ended and generics are crushing the brand. Novartis's Q2 2026 results (SEC 6-K, July 2026) reported Entresto sales down ~51% in constant currency on US generic competition, a disclosed headwind the company is offsetting with other growth products. With no pending approval decision or pivotal readout for Entresto, the investment read is a steady, known decline rather than a binary catalyst — modest for a diversified ~$285B company.
Explore drug →
2 drug reports
-
Tecarfarin is Cadrenal Therapeutics' (Nasdaq: CVKD) late-stage oral cardiovascular asset, currently framed as the "orphan regulatory acceleration" pillar of a ~$6M market-cap, pre-revenue pipeline being shopped to partners. In June 2026 the company announced it would file for FDA Rare Pediatric Disease Designation for tecarfarin in Kawasaki disease — which, if granted and followed by approval, would make it eligible for a Priority Review Voucher reportedly worth $180M–$205M, multiples of the company's entire market cap. However, there is no dated regulatory binary in the next 12 months, no revenue, roughly $4M cash at 2025 year-end, a recent ~33%-dilutive private placement, an effective S-3 shelf, and CEO insider selling — so the drug is genuine optionality at a heavily distressed micro-cap, not a near-term catalyst.
Explore drug → -
CAD-1005 is Cadrenal Therapeutics' (CVKD, Nasdaq, ~$1.66/share, ~$6M market cap) lead drug: an oral 12-LOX inhibitor being developed for heparin-induced thrombocytopenia (HIT), a rare, life-threatening clotting complication of heparin with no HIT-specific FDA-approved drug. It holds FDA Fast Track and Orphan Drug designations, posted Phase 2 data with a >25% absolute reduction in thrombotic events, and the FDA's End-of-Phase 2 meeting green-lit a pivotal Phase 3 path with an NDA submission projected for 2029. The company has no revenue, ~$4M cash (year-end 2025) that management said may not fund Phase 3, and just did a ~33%-dilutive $3M placement — it has also launched a partnering process to out-license or co-develop CAD-1005 (alongside tecarfarin and frunexian).
Explore drug →
Gozellix (TLX007-CDx) is Telix Pharmaceuticals' second-generation PSMA-PET imaging agent for prostate cancer — a kit for preparing gallium-68 gozetotide injection — approved by the FDA on March 21, 2025 under a 505(b)(2) NDA and launched in the US in June 2025. It is a commercial success so far: Telix hit upgraded FY2025 revenue guidance of ~US$804M (Q4 up 46% YoY, partly driven by the Gozellix launch) and H1 2026 Precision Medicine revenue rose 27% YoY on the two-product Illuccix/Gozellix strategy. The stock trades around US$12.12 (Nasdaq: TLX) with analyst price targets implying meaningful upside, but Gozellix's defining binary has passed and the next major TLX catalysts belong to Telix's therapy pipeline, not this diagnostic.
AP-SA02 is Armata Pharmaceuticals' (NYSE American: ARMP) lead candidate: an IV phage cocktail against Staphylococcus aureus bacteremia, a serious antibiotic-resistance problem. Its Phase 2 study is complete, the FDA has agreed to the initial pediatric study plan (a required step toward a future BLA), and the Phase 3 superiority protocol was submitted in July 2026 with study initiation targeted for H2 2026. Armata is pre-revenue and funds development via a $25M Innoviva secured credit facility (14% interest) plus a $28.7M DoD award, and the stock trades around $5.07 (roughly $166M market cap) versus a ~$17.5 mean analyst price target — a wide gap reflecting a long, high-risk timeline with no near-term pivotal binary.
z-rostudirsen (formerly DYNE-251) is Dyne Therapeutics' lead asset: an exon-51-skipping therapy for a subset of Duchenne muscular dystrophy patients, backed by positive Phase 1/2 DELIVER data and now under FDA Priority Review with a PDUFA date of January 21, 2027 — a potential first approval/launch for the company in Q1 2027. The setup is genuinely bullish: BLA accepted, strong analyst consensus and broad Q2 2026 institutional accumulation. But it carries real bear risks: approval rests on a surrogate endpoint with a confirmatory Phase 3 (FORZETTO) still enrolling, the July 2026 equity offering diluted shareholders ~9-11%, and insiders (led by Atlas Venture) have been selling large blocks under 10b5-1 plans.
EIK1001 is Eikon Therapeutics' (Nasdaq: EIKN) lead candidate, a TLR7/8 agonist in Phase 2 for first-line non-small cell lung cancer, with a registrational trial in melanoma. At ASCO 2026 the company reported a 63.1% overall response rate and 90.8% disease control rate across 65 evaluable NSCLC patients, and it has guided to melanoma registrational-trial interim analyses plus Phase 2 NSCLC readouts in 2H 2026. The stock trades at $12.01 (8/19/26) with a bullish analyst consensus (mean target $24.6) but persistent bearish signals: Wedbush's Underperform rating, rising short interest, high short-volume flow, and a history of ~12% declines on prior neutral clinical filings.
2 drug reports
-
BYOOVIZ (ranibizumab-nuna) is an FDA-approved, interchangeable biosimilar of Lucentis that Harrow, Inc. (Nasdaq: HROW), a Nashville-based ophthalmic company, began selling in the US on July 1, 2026 as the anchor of its growing retina portfolio. It is already commercialized — the defining regulatory binary has passed — so the investment question is execution: how fast BYOOVIZ (plus VEVYE, IHEEZO, and the pending TYRVAYA acquisition) can drive Harrow's reiterated $350M-$365M 2026 revenue guidance, which implies a steep second-half ramp. Company-level signals are mixed: analysts rate the stock strong-buy (mean PT $67.50 vs. $41.64 close), and several funds added Q2 2026 13F positions, but FINRA data show ~18.2% of estimated shares outstanding short and heavy daily short-volume flow, while Q2 2026 swung to a $17.3M GAAP net loss on heavy sales-force/R&D investment.
Explore drug → -
IHEEZO is Harrow, Inc.'s (Nasdaq: HROW) branded chloroprocaine HCl ophthalmic gel 3%, a low-viscosity ocular anesthetic gel used to numb the eye for ophthalmic procedures; it won FDA approval on September 27, 2022 and is commercially marketed. It is a growing but supporting asset inside a portfolio led by VEVYE: Q2 2026 earnings reported record IHEEZO unit demand (+44% sequential, +34% YoY) and a ~25% net price improvement effective July 1, 2026, and three studies (interim randomized patient-experience data plus a large real-world safety analysis) were presented at ASRS 2026. There is no IHEEZO-specific binary catalyst on the calendar, and the company is burning cash (GAAP net loss -$17.3M in Q2 2026, -$18.7M operating cash flow YTD) to fund an aggressive H2 ramp, so the drug reads as a solid commercial grower rather than a stock-moving binary.
Explore drug →
neffy (epinephrine nasal spray, development code ARS-1) is the first FDA-approved needle-free epinephrine for Type I allergic reactions including anaphylaxis, approved Aug 2024 and now labeled for everyone weighing ≥33 lbs with no age cap (March 2026), plus approved in Canada (April 2026). Developer ARS Pharmaceuticals (Nasdaq: SPRY) is a single-product company ramping sales — US neffy net product revenue was $72.2M in FY2025, $17.5M in Q1 2026 (+125% YoY) and $26.2M in Q2 2026 — but it holds only ~5% of the total US epinephrine market for Type 1 allergies. The big overhang: CVS Caremark deferred its neffy coverage decision to January 2027, the stock fell 23.9% on June 25, 2026 when that was disclosed, and multiple securities class actions followed; the stock trades near $6.38 versus a $23.25 mean analyst price target.
3 drug reports
-
RGX-111 is REGENXBIO Inc.'s (Nasdaq: RGNX) investigational one-time gene therapy for MPS I (Hurler syndrome), and it is in deep trouble: the FDA placed the Phase I/II program on clinical hold in January 2026 after a trial participant developed a neoplasm (tumor), and no resolution of the hold is recorded in SecBot data through the August 2026 Q2 report. It is a minor program inside a larger pipeline — RGNX's near-term value drivers are the RGX-202 Duchenne BLA (Q3 2026), pivotal wet-AMD topline data (Q4 2026) and the RGX-121 BLA resubmission (Q3 2026) — so RGX-111 alone is unlikely to move the stock much.
Explore drug → -
NAVSUNLI (clemidsogene lanparvovec, code RGX-121) is REGENXBIO's one-time AAV9 gene therapy for Hunter syndrome (MPS II) and would be the first gene therapy / first one-time treatment for the disease if approved. The FDA rejected the original BLA around its Feb 8, 2026 PDUFA date, then reversed course on June 22, 2026 and aligned on a path to resubmit for accelerated approval with no additional studies required; REGENXBIO guided the resubmission to Q3 2026 with a positive Type A meeting, implying a decision roughly 6 months later. The drug carries Orphan, Rare Pediatric Disease, Fast Track and RMAT designations and is partnered with Nippon Shinyaku, but it competes with Takeda's weekly-infusion enzyme therapy Avlayah, and REGENXBIO shares are volatile and diluted (a July 2026 ~$108M offering) with other big catalysts (RGX-202, sura-vec) competing for attention.
Explore drug → -
RGX-202 is REGENXBIO's (Nasdaq: RGNX) Phase 3 gene therapy for Duchenne muscular dystrophy, and its pivotal AFFINITY DUCHENNE study hit its primary endpoint with high statistical significance (p<0.0001; 93% of patients reached >10% microdystrophin expression) with a functional-improvement correlation, per the company's May 14, 2026 release. Management says a BLA submission will begin in Q3 2026 with potential accelerated approval in 2H 2027. The stock (~$12, 52-wk range $5.46-$16.19) already carries a bullish analyst setup (17 buy/strong-buy ratings vs 2 holds; mean PT $22.80), but the company burned cash, diluted holders ~17-20% in a July 2026 offering, and operates under an FDA that recently CRL'd its RGX-121 over surrogate-endpoint concerns — so the net read is mixed.
Explore drug →
2 drug reports
-
Camlipixant (development code BLU-5937) was GSK's $2B-plus bet in the P2X3 antagonist race for refractory chronic cough, a drug acquired with Bellus Health. The binary outcome already landed badly: the confirmatory Phase 3 CALM-2 trial missed its primary endpoint at week 24 even though the first study (CALM-1) hit at week 12, and GSK has discontinued the program in chronic cough. The failure forced a roughly £1.9B impairment that cut GSK's Q2 2026 operating profit about 75%, though GSK reaffirmed full-year guidance and the stock remains near its highs — a measure of how small one failed drug is inside a ~$100B company. A Phase IIb IBS program is the only thing left for the molecule.
Explore drug → -
Neladalkib is Nuvalent's late-stage ALK-inhibitor pill for TKI pre-treated advanced ALK-positive non-small cell lung cancer. Its NDA was submitted to the FDA in May 2026 and accepted with Priority Review; the PDUFA target action date is November 27, 2026. GSK plc agreed on June 9, 2026 to buy Nuvalent for $124.00 per share in cash (~$10.6 billion total equity value, ~40% premium), and the merger closed July 15, 2026, so the drug now belongs to GSK's oncology franchise alongside ROS1 drug zidesamtinib (PDUFA September 18, 2026) and phase I HER2 asset NVL-330.
Explore drug →
Briquilimab is Jasper Therapeutics' (Nasdaq: JSPR) anti-c-Kit antibody for mast-cell-driven diseases (chronic spontaneous urticaria, CIndU, asthma) and SCID conditioning. The stock has been transformed in 2026: after a June 2026 strategic-alternatives review at ~$23M market cap, Jasper closed an all-stock acquisition of Kira Pharmaceuticals with a $132M PIPE, leaving legacy Jasper holders at only ~6.68% of the combined company and making Kira's KP-104 the pipeline lead; legacy holders received non-tradeable CVRs worth a $30M payout only if the FDA issues a Priority Review Voucher for briquilimab by Dec 31, 2028. The most immediate briquilimab event is an imminent Phase 2 CSU readout (trial completed July 8, 2026, results unposted), with a dated BLA-path update flagged for Q1 2027.
Prexigebersen is Bio-Path Holdings' (BPTH, OTC, ~$0.035/share) lead Phase 2 oncology asset — but the company is effectively abandoning it: 2026 8-K analyses show a radical pivot from biotech to a crypto "Digital Asset Treasury 2.0" business, non-binding LOIs to sell the biotech IP, only ~$28,000 raised from recent Regulation A sales, and over $355,000 owed to MD Anderson just to restart the Phase 2 trials, plus a standing dilution overhang from 5 million Series B Preferred shares (each convertible into 1,000 common shares). The stock is down ~68% over 12 months with a strong bearish technical trend.
ASCENIV is ADMA Biologics' lead and dominant product, an FDA-approved intravenous immune globulin (IVIG) for primary humoral immunodeficiency; on May 4, 2026 the FDA approved a label expansion to pediatric patients aged 2+. It drove record 2025 results (revenue ~$510M, +20% YoY). The stock has been volatile since a March 2026 Culper Research short-seller report accused ADMA of channel stuffing, followed by securities-fraud class actions (announced by Berger Montague and other firms) covering Aug 9, 2024–Mar 25, 2026; ADMA has denied the allegations.
Teverelix is Medicus Pharma's (Nasdaq: MDCX) investigational long-acting injectable GnRH antagonist, positioned across three Phase 2 programs: acute urinary retention/BPH (~$2B claimed target market), high cardiovascular-risk prostate cancer (~$4B claimed market), and endometriosis via a genomics-guided Phase 2a in the UAE. The program is advancing on process milestones — positive FDA feedback and IRB approval for a slimmer 126-patient Phase 2 design (July 2026) and European filing for a 2026 Phase 2b start — but no efficacy readout or regulatory decision is scheduled, and the sponsor is a micro-cap with a disclosed going-concern doubt ($6.4M cash, $9.0M Q1 2026 net loss, expanded ATM). Net read: real optionality, no imminent binary, severe financing risk.
Travelan is Immuron's flagship product — an over-the-counter immune supplement made from cow colostrum (first milk) containing antibodies against the E. coli (ETEC) that causes travelers' diarrhea. It is already sold in the US, Australia, Canada and elsewhere, with global FY2026 (ended June 30, 2026) sales of ~AUD$7.7 million, up 6% year-over-year on four straight quarters of growth. Separately, Immuron is pursuing the same active ingredient (IMM-124E) as a regulated FDA drug: a Phase 2 controlled human infection trial (NCT05933525, n=63) is complete and a Phase 2 study report was submitted to the FDA, but a large US military trial (P2TD, n=851) of a third-party-manufactured version missed its primary endpoint, which the company blamed on non-standard dosing and poor compliance. The stock trades around $1.15 with thin coverage (one analyst, ~$3.96 target) — real commercial momentum, but regulatory upside remains years away and unproven.
AVZO-021 is the lead oncology drug of private biotech Avenzo Therapeutics, which is reverse-merging into Nasdaq-listed Rallybio Corp (RLYB) under a definitive agreement signed May 31, 2026: Rallybio will distribute substantially all its net cash (~$83.2M, ~$15.7/share) to legacy holders plus CVRs, and rename itself Avenzo Therapeutics, Inc. (expected ticker AVZO), with a $215M concurrent PIPE and a Q4 2026 expected close (S-4, 8-K, Form 425). Legacy Rallybio holders will own only ~2.8% of the combined company, so AVZO-021's share-price leverage for today's RLYB holders is small and indirect.
Tirzepatide (Mounjaro/Zepbound, development code LY3298176) is Eli Lilly's (NYSE: LLY, verified via SEC filings as ELI LILLY & Co) blockbuster dual GIP/GLP-1 incretin injection, approved in the U.S. for type 2 diabetes (May 2022) and obesity (Nov 2023). Per Lilly's Q2 2026 earnings filing (8-K filed 2026-08-05), Mounjaro generated $9.9B (+91% YoY) and Zepbound $4.9B (+46%) in the quarter, driving total revenue of $22.97B (+48%) and a raised full-year revenue guide of $85–87B — the drug is the company's growth engine. It is a commercial juggernaut rather than a binary-stage asset: both approvals have passed, no dated regulatory catalyst is confirmed for the next ~12 months from this session's data, and the stock (~$1,225.73 on 2026-08-18, near its 52-week high of $1,249.45) trades on continued growth, competition (Novo Nordisk's semaglutide and next-gen CagriSema, plus Lilly's own retatrutide) and label-expansion optionality (CV outcomes, CKD, type 1 diabetes).
NEO212 is NeOnc Technologies' oral temozolomide-perillyl alcohol conjugate for aggressive brain tumors, one of two lead programs (alongside intranasal NEO100) at this ~$113M market-cap, pre-revenue Nasdaq biotech (NTHI). Phase 1 is complete with a 610 mg recommended Phase 2 dose; NEO212 has FDA CMC alignment in progress (constructive written feedback in July 2026) and a first international IND clearance from Abu Dhabi, but no Phase 2 enrollment or dated readout yet. The stock's recent August 2026 catalysts — the Phase 2a topline (48.9% six-month PFS vs 20% benchmark) and insider buying — center on the separate NEO100 program and the CEO's open-market purchases, respectively.
VDPHL01 is Veradermics' (NYSE: MANE) lead and essentially only program: an oral extended-release minoxidil pill for pattern hair loss in men and women, developed by a company that IPO'd in April 2026 and is already valued at roughly $4.6B. Clinical data so far are consistently positive — a Phase 2/3 male study hit all primary and key secondary endpoints, and a Phase 2 female study showed double-digit hair-count gains at Month 6 — and two pivotal readouts are scheduled (Study 304 topline 2H26, Study 306 topline 1H27). The offsetting risks are pure share-structure and financing: an August 2026 resale S-1 registered ~40.6% of shares outstanding for sale by holders (company gets no proceeds), a director sold ~$10.7M of stock in mid-August, short interest stood at 11.54% of estimated shares outstanding (7/31/26 settlement) and rising, and there is zero revenue with widening losses.
SENTI-202 is Senti Biosciences' lead asset: a Logic-Gated CAR-NK cell therapy for relapsed/refractory acute myeloid leukemia. The drug has real momentum — RMAT designation, positive FDA feedback finalizing a single-arm registrational trial path, and Phase 1 data (50% composite CR with Donor X NK cells vs 12.5% without, durable MRD-negative remissions up to 21+ months). However, the investor picture for SNTI is dominated by corporate structure: in July 2026 Senti agreed with a Celadon affiliate to spin SENTI-202 into a private company, leaving SNTI as a thinly-funded public shell whose shareholders receive only contingent value rights (up to $60M in milestones).
RT-114 is Rani Therapeutics' (Nasdaq: RANI) oral RaniPill capsule version of PG-102, a GLP-1/GLP-2 dual agonist licensed from South Korea's ProGen, aimed at obesity. Positive initial Phase 1a data (July 15, 2026) showed oral exposure exceeding a matched subcutaneous dose, validating the delivery platform but leaving the drug at the earliest clinical stage; Phase 1b obesity data is only expected in 2027. RANI is a ~$0.85 stock (52-week range $0.44–$3.87) with a heavily-diluted, small-cap profile, insider buying, a Chugai collaboration backing the balance sheet, and analyst price targets far above the market price — a speculative mixed risk/reward.
IMAAVY is J&J's brand for nipocalimab, an anti-FcRn antibody already approved (FDA approval catalyst recorded 2025-04-29) with a second NDA filed 2026-04-14 for warm autoimmune hemolytic anemia and Fast Track in SLE — a genuine label-expansion story at a blue-chip. But at Johnson & Johnson's scale the drug barely moves the stock (approval day +0.62%, NDA filing +0.3%), no wAIHA PDUFA date is on record yet, and the gMG/wAIHA fields are crowded (VYVGART/VYVGART Hytrulo, cemdisiran, UPLIZNA, sovleplenib, povetacicept). Net investor read: a real but minor, slow-burn driver — mixed.
Showing 30 of 251 reports